Spanish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

PRogetto Salute Parma

Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
El enlace se guarda en el portapapeles.
EstadoReclutamiento
Patrocinadores
University of Parma
Colaboradores
Azienda Ospedaliero-Universitaria di Parma
Azienda Unità Sanitaria Locale (AUSL) di Parma

Palabras clave

Abstracto

This project from the University Hospital of Parma (AOUPR) aims to verify the feasibility of a prevention program in our district, relying on advanced technological resources and highly experienced team in lung cancer early diagnosis, in order to identify useful elements towards the applicability of such a prevention program on a large scale (regional, national).
Uncontrolled, monocentric experimental study with dynamic enrollment and prospective data collection, aimed at implementing a prevention program based on scientific evidence. This study is set to verify the applicability and feasibility of a lung cancer prevention program in a real context, including a preliminary evaluation at the smoking cessation clinic and a LDCT assessment with subsequent LDCT follow-up for participants who show indeterminate findings at the first LDCT (LDCT baseline) exam.
The main objective of the study is to verify the feasibility of a lung cancer prevention program according to internationally validated scientific methods.
Secondary objectives:
1. To evaluate the use of local smoking cessation clinics and their effects in terms of smoking cessation (primary prevention)
2. To evaluate the outcomes of the program in terms of number of patients with early (presymptomatic) lung cancer treated with minimally invasive surgery (secondary prevention)
3. To evaluate the number of false positives and their diagnostic work-up (PET-CT, CT-guided biopsy, bronchoscopy)
Primary endpoint:
- Percentage of enrolled subjects to whom the program was offered within 60 days from the date of enrolment and percentage of those who stop smoking for at least 12 months
Secondary endpoints:
- To describe the organizational model, human resources employed, difficulties encountered and elements that have favoured its realization
- To measure the variation in smoking habits in enrolled smokers
- To describe the effect of annual LDCT on lung cancer diagnosis rates, considering size, shape, histology and site
- To measure the consequent demand for further diagnostic investigations and treatment
- To measure the number of false positives
Subjects at high risk of lung cancer screened by the medical team of the AOUPR or by GPs to join the prevention program.
Inclusion criteria
- Age between 50 and 75 years
- Equivalent tobacco intoxication of ≥ 15 cigarettes per day for ≥25 years or ≥ 10 cigarettes per day for ≥30 years
- Status of current smoker or ex-smoker for <10 years.
Exclusion criteria
• Personal history of cancer within the prior 5 years
We expect to recruit around 500 people in 1 year. This sample size is considered adequate based on the available resources, both human and economic.
After closing and adjusting the database and before data analysis, a document called Statistical Analysis Plan (SAP) will be drawn up. It will consist of the following paragraphs:
- Statistical methods planned in the study protocol;
- Size of the sample;
- Management of missing data;
- Evaluation of the endpoints;
- Statistical models that will be applied in the analysis. The socio-demographic characteristics of the enrolled subjects, the adopted organizational methods and the effects of the prevention program (endpoints) will be analyzed and described using tables and figures.
The project "PRogetto Salute Parma: Primary and secondary prevention of smoking-related lung cancer" will be started once approved by the institutional Ethics Committee and authorized by the General Manager. The study is expected to be carried out over 2 years (from the inclusion of the first subject), with an expected period of 1 year for the enrolment and 1 further year for follow-up.

fechas

Verificado por última vez: 01/31/2020
Primero enviado: 02/19/2020
Inscripción estimada enviada: 02/19/2020
Publicado por primera vez: 02/24/2020
Última actualización enviada: 02/19/2020
Última actualización publicada: 02/24/2020
Fecha de inicio real del estudio: 02/11/2020
Fecha estimada de finalización primaria: 01/31/2021
Fecha estimada de finalización del estudio: 01/31/2022

Condición o enfermedad

Smoking
Smoking Habit
Smoking, Tobacco
Smoking, Cigarette
Smoking Cessation
Lung Cancer

Intervención / tratamiento

Diagnostic Test: High risk (former) smokers

Fase

-

Grupos de brazos

BrazoIntervención / tratamiento
High risk (former) smokers
Subjects at high risk of lung cancer screened by the medical team of the AOUPR or by GPs to join the prevention program. Inclusion criteria Age between 50 and 75 years Equivalent tobacco intoxication of ≥ 15 cigarettes per day for ≥25 years or ≥ 10 cigarettes per day for ≥30 years Status of current smoker or ex-smoker for <10 years. Exclusion criteria • Personal history of cancer within the prior 5 years
Diagnostic Test: High risk (former) smokers
Early detection of lung cancer by LDCT and smoking cessation counselling

Criterio de elegibilidad

Edades elegibles para estudiar 50 Years A 50 Years
Sexos elegibles para estudiarAll
Método de muestreoProbability Sample
Acepta voluntarios saludablessi
Criterios

Inclusion Criteria:

- Equivalent tobacco intoxication of ≥ 15 cigarettes per day for ≥25 years or ≥ 10 cigarettes per day for ≥30 years

- Status of current smoker or ex-smoker for <10 years.

Exclusion Criteria:

- Personal history of cancer within the prior 5 years

Salir

Medidas de resultado primarias

1. Adherence [12 months]

Percentage of enrolled subjects to whom the program was offered within 60 days from the date of enrolment and percentage of those who stop smoking for at least 12 months

Medidas de resultado secundarias

1. Organization model [18 months]

To describe the organizational model, human resources employed, difficulties encountered and elements that have favoured its realization

2. Smoking cessation [24 months]

To measure the variation in smoking habits in enrolled smokers.

3. Secondary prevention of lung cancer [24 mesi]

To describe the effect of annual LDCT on lung cancer diagnosis rates, considering size, shape, histology and site.

4. Work up burden [24 months]

To measure the demand for further diagnostic investigations and treatment generated by LDCT.

5. False positives [24 months]

To measure the number of false positives generated by LDCT

Únete a nuestra
página de facebook

La base de datos de hierbas medicinales más completa respaldada por la ciencia

  • Funciona en 55 idiomas
  • Curas a base de hierbas respaldadas por la ciencia
  • Reconocimiento de hierbas por imagen
  • Mapa GPS interactivo: etiquete hierbas en la ubicación (próximamente)
  • Leer publicaciones científicas relacionadas con su búsqueda
  • Buscar hierbas medicinales por sus efectos.
  • Organice sus intereses y manténgase al día con las noticias de investigación, ensayos clínicos y patentes.

Escriba un síntoma o una enfermedad y lea acerca de las hierbas que podrían ayudar, escriba una hierba y vea las enfermedades y los síntomas contra los que se usa.
* Toda la información se basa en investigaciones científicas publicadas.

Google Play badgeApp Store badge